Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: Effects on the degradation of RARα and PML-RARα

Maurizio Gianni', Yesim Kalaç, Isabella Ponzanelli, Alessandro Rambaldi, Mineko Terao, Enrico Garattini

Research output: Contribution to journalArticle

Abstract

The 2-phenylaminopyrimidine derivative STI571 is a selective inhibitor of c-Abl, c-kit, and platelet-derived growth factor-receptor tyrosine kinases and is presently in phase II-III clinical studies. Here, this study reports on a novel pharmacologic activity of the compound, ie, enhancement of the cyto-differentiating, growth-inhibitory, and apoptogenic actions of all-trans-retinoic acid (ATRA). Whereas STI571 is not a cytodifferentiating agent by itself, the compound interacts with ATRA and enhances the myeloid maturation program set in motion by the retinoid in the PML-RARα+ acute promyelocytic leukemia NB4 and the PML-RARα- myeloblastic HL60 and U937 cell lines. In addition, STI571 relieves the cytodifferentiation block observed in the ATRA-resistant cell lines, NB4.R1, NB4.306, and NB4.007. In NB4 promyelocytes, a RARα agonist, but not an RXR agonist, can substitute for ATRA and interact with STI571. By contrast, STI571 is unique among c-Abl-specific tyrosine kinase inhibitors in modulating the pharmacologic activity of ATRA. In NB4 cells, enhanced cyto-differentiation results in increased up-regulation of the expression of a number of genes coding for myeloid differentiation markers, including CD11b, CD11c, and some of the components of the nicotinamide adenine dinucleotide phosphate-oxidase enzymatic complex. All this is accompanied by inhibition of c-Abl tyrosine phosphorylation and retardation of the retinoid-dependent degradation of PML-RARα and RARα. Stabilization of the 2 retinoic acid receptors is likely to be the result of augmented and accelerated inhibition of the proteasome-dependent proteolytic activity observed on ATRA treatment.

Original languageEnglish
Pages (from-to)3234-3243
Number of pages10
JournalBlood
Volume97
Issue number10
DOIs
Publication statusPublished - May 15 2001

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Protein-Tyrosine Kinases
Degradation
Retinoids
Cells
Cell Line
Granulocyte Precursor Cells
U937 Cells
Retinoic Acid Receptors
Phosphorylation
HL-60 Cells
Differentiation Antigens
Proteasome Endopeptidase Complex
NADP
Tyrosine
Imatinib Mesylate
Oxidoreductases
Up-Regulation
Stabilization

ASJC Scopus subject areas

  • Hematology

Cite this

Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells : Effects on the degradation of RARα and PML-RARα. / Gianni', Maurizio; Kalaç, Yesim; Ponzanelli, Isabella; Rambaldi, Alessandro; Terao, Mineko; Garattini, Enrico.

In: Blood, Vol. 97, No. 10, 15.05.2001, p. 3234-3243.

Research output: Contribution to journalArticle

@article{3166e32301664a8e8705c85847cdc387,
title = "Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: Effects on the degradation of RARα and PML-RARα",
abstract = "The 2-phenylaminopyrimidine derivative STI571 is a selective inhibitor of c-Abl, c-kit, and platelet-derived growth factor-receptor tyrosine kinases and is presently in phase II-III clinical studies. Here, this study reports on a novel pharmacologic activity of the compound, ie, enhancement of the cyto-differentiating, growth-inhibitory, and apoptogenic actions of all-trans-retinoic acid (ATRA). Whereas STI571 is not a cytodifferentiating agent by itself, the compound interacts with ATRA and enhances the myeloid maturation program set in motion by the retinoid in the PML-RARα+ acute promyelocytic leukemia NB4 and the PML-RARα- myeloblastic HL60 and U937 cell lines. In addition, STI571 relieves the cytodifferentiation block observed in the ATRA-resistant cell lines, NB4.R1, NB4.306, and NB4.007. In NB4 promyelocytes, a RARα agonist, but not an RXR agonist, can substitute for ATRA and interact with STI571. By contrast, STI571 is unique among c-Abl-specific tyrosine kinase inhibitors in modulating the pharmacologic activity of ATRA. In NB4 cells, enhanced cyto-differentiation results in increased up-regulation of the expression of a number of genes coding for myeloid differentiation markers, including CD11b, CD11c, and some of the components of the nicotinamide adenine dinucleotide phosphate-oxidase enzymatic complex. All this is accompanied by inhibition of c-Abl tyrosine phosphorylation and retardation of the retinoid-dependent degradation of PML-RARα and RARα. Stabilization of the 2 retinoic acid receptors is likely to be the result of augmented and accelerated inhibition of the proteasome-dependent proteolytic activity observed on ATRA treatment.",
author = "Maurizio Gianni' and Yesim Kala{\cc} and Isabella Ponzanelli and Alessandro Rambaldi and Mineko Terao and Enrico Garattini",
year = "2001",
month = "5",
day = "15",
doi = "10.1182/blood.V97.10.3234",
language = "English",
volume = "97",
pages = "3234--3243",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells

T2 - Effects on the degradation of RARα and PML-RARα

AU - Gianni', Maurizio

AU - Kalaç, Yesim

AU - Ponzanelli, Isabella

AU - Rambaldi, Alessandro

AU - Terao, Mineko

AU - Garattini, Enrico

PY - 2001/5/15

Y1 - 2001/5/15

N2 - The 2-phenylaminopyrimidine derivative STI571 is a selective inhibitor of c-Abl, c-kit, and platelet-derived growth factor-receptor tyrosine kinases and is presently in phase II-III clinical studies. Here, this study reports on a novel pharmacologic activity of the compound, ie, enhancement of the cyto-differentiating, growth-inhibitory, and apoptogenic actions of all-trans-retinoic acid (ATRA). Whereas STI571 is not a cytodifferentiating agent by itself, the compound interacts with ATRA and enhances the myeloid maturation program set in motion by the retinoid in the PML-RARα+ acute promyelocytic leukemia NB4 and the PML-RARα- myeloblastic HL60 and U937 cell lines. In addition, STI571 relieves the cytodifferentiation block observed in the ATRA-resistant cell lines, NB4.R1, NB4.306, and NB4.007. In NB4 promyelocytes, a RARα agonist, but not an RXR agonist, can substitute for ATRA and interact with STI571. By contrast, STI571 is unique among c-Abl-specific tyrosine kinase inhibitors in modulating the pharmacologic activity of ATRA. In NB4 cells, enhanced cyto-differentiation results in increased up-regulation of the expression of a number of genes coding for myeloid differentiation markers, including CD11b, CD11c, and some of the components of the nicotinamide adenine dinucleotide phosphate-oxidase enzymatic complex. All this is accompanied by inhibition of c-Abl tyrosine phosphorylation and retardation of the retinoid-dependent degradation of PML-RARα and RARα. Stabilization of the 2 retinoic acid receptors is likely to be the result of augmented and accelerated inhibition of the proteasome-dependent proteolytic activity observed on ATRA treatment.

AB - The 2-phenylaminopyrimidine derivative STI571 is a selective inhibitor of c-Abl, c-kit, and platelet-derived growth factor-receptor tyrosine kinases and is presently in phase II-III clinical studies. Here, this study reports on a novel pharmacologic activity of the compound, ie, enhancement of the cyto-differentiating, growth-inhibitory, and apoptogenic actions of all-trans-retinoic acid (ATRA). Whereas STI571 is not a cytodifferentiating agent by itself, the compound interacts with ATRA and enhances the myeloid maturation program set in motion by the retinoid in the PML-RARα+ acute promyelocytic leukemia NB4 and the PML-RARα- myeloblastic HL60 and U937 cell lines. In addition, STI571 relieves the cytodifferentiation block observed in the ATRA-resistant cell lines, NB4.R1, NB4.306, and NB4.007. In NB4 promyelocytes, a RARα agonist, but not an RXR agonist, can substitute for ATRA and interact with STI571. By contrast, STI571 is unique among c-Abl-specific tyrosine kinase inhibitors in modulating the pharmacologic activity of ATRA. In NB4 cells, enhanced cyto-differentiation results in increased up-regulation of the expression of a number of genes coding for myeloid differentiation markers, including CD11b, CD11c, and some of the components of the nicotinamide adenine dinucleotide phosphate-oxidase enzymatic complex. All this is accompanied by inhibition of c-Abl tyrosine phosphorylation and retardation of the retinoid-dependent degradation of PML-RARα and RARα. Stabilization of the 2 retinoic acid receptors is likely to be the result of augmented and accelerated inhibition of the proteasome-dependent proteolytic activity observed on ATRA treatment.

UR - http://www.scopus.com/inward/record.url?scp=0035874492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035874492&partnerID=8YFLogxK

U2 - 10.1182/blood.V97.10.3234

DO - 10.1182/blood.V97.10.3234

M3 - Article

C2 - 11342454

AN - SCOPUS:0035874492

VL - 97

SP - 3234

EP - 3243

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -